Press Releases
Biological Dynamics, Inc., a leader in exosome technology, today announced that Hoag has joined the growing list of customers adopting Biological Dynamics’ ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform. ExoVerita Pro supports exosome-based research efforts, helping to accelerate early disease detection, determine therapeutic response, and more.
Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, today announced that its ExoLuminate Study is expanding subject enrollment with the addition of four leading institutions in cancer treatment and research: the Dana-Farber Cancer Institute; Moores Cancer Center at UC San Diego Health; University of Florida Health; and MedStar Georgetown.
Media Spotlight
This interview discusses Biological Dynamics, its technology, and it’s future directions.
Biological Dynamics Is Transforming Exosome Research and Advancing Liquid Biopsy with Its Proprietary ExoVerita Pro Platform
Biological Dynamics, a privately held San Diego-based company, is poised to revolutionize exosome/extracellular vesicle (EV) isolation and enrichment by addressing current research challenges and ultimately driving new liquid biopsy advancements. Biological Dynamics has developed an automated bench-top device, ExoVerita Pro, that uses alternating current electrokinetics (ACE) (see details below) to separate exosomes/EVs from other material in small samples of plasma (50-250 µL). The platform offers a simple and automated workflow to enrich exosomes and EVs, bypassing many fundamental limitations of current isolation technologies. This technology is superior to the current exosome/EV separation methods such as ultracentrifugation and column purification in terms of purity and reproducibility and in process time, reducing it from days to hours.
Upcoming Events
Visit Biological Dynamics at Booth 10071.
Attend the 2024 ASCO Annual Meeting and be part of the most significant gathering of oncology professionals worldwide, making connections and forging collaborations that can change the landscape of cancer care.